Abstract:New Findings What is the central question of this study? In this study, we investigated whether MD1 interacted with the sympathetic nerves in ventricular arrhythmia (VA) during heart failure with preserved ejection fraction (HFpEF). What is the main finding and its importance? Mice with HFpEF showed increased susceptibility to VA, adverse electrical remodelling, impaired heart rate variability, enhanced sympathetic hyperactivity, activation of the NLRP3 inflammasome and increased interleukin‐1β release. These changes induced by HFpEF were exacerbated by MD1 deficiency. AbstractSympathetic hyperactivity can promote malignant ventricular arrhythmia (VA), and myeloid differentiation 1 (MD1) has been reported to play an important role in obesity‐induced VA. However, it is not known whether an interaction of MD1 with sympathetic hyperactivity contributes to the VA induced by heart failure with preserved ejection fraction (HFpEF). The aim of this study was to investigate the potential interaction between MD1 and sympathetic hyperactivity in HFpEF‐induced VA and the underlying mechanism. Eight‐week‐old MD1‐knockout (MD1‐KO) and wild‐type (WT) mice were subjected to a model of HFpEF induced by uninephrectomy, a continuous saline or d‐aldosterone infusion and provision of drinking water containing 1.0% sodium chloride for 4 weeks. Echocardiography and haemodynamics were used to verify the model of HFpEF. An isolated electrophysiological study was performed to assess the susceptibility to VA. Four weeks later, the mice with HFpEF showed an increased heart weight to tibia length ratio, decreased left ventricular minimum rates of pressure rise (dP/dtmin), increased τ, lung weight to tibia length ratio and preserved left ventricular ejection fraction compared with WT mice. The mice with HFpEF exhibited increased susceptibility to VA, as shown by the shortened effective refractory period, prolonged action potential duration (APD), increased APD alternans threshold and higher incidence of VA. Moreover, we also found that mice with HFpEF showed impaired heart rate variability, sympathetic hyperactivity, activation of the NLRP3 inflammasome and increased interleukin‐1β release. These changes induced by HFpEF were exacerbated by MD1 deficiency. We conclude that MD1‐KO contributes to sympathetic hyperactivity and facilitates VA in HFpEF via activation of the NLRP3 inflammasome. Treatment targeting MD1 and NLRP3 might decrease the risk of HFpEF‐induced VA.

MCC950 Ameliorates Ventricular Arrhythmia Vulnerability Induced by Heart Failure

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice

Theoretical Investigation Of The Mechanism Of Heart Failure Using A Canine Ventricular Cell Model: Especially The Role Of Up-Regulated Camkii And Sr Ca2+ Leak

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model

A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury

Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation

The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence

The Selective NLRP3-inflammasome Inhibitor MCC950 Reduces Myocardial Fibrosis and Improves Cardiac Remodeling in a Mouse Model of Myocardial Infarction.

MCC950 Reduces Neuronal Apoptosis in Spinal Cord Injury in Mice

MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation

MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis

Effect of Calcium-Sensing Receptor Inhibition on the Vulnerability of Ventricular Arrhythmia in a Rat Model of Chronic Heart Failure

The Selective NLRP3-inflammasome Inhibitor MCC950 Mitigates Post-resuscitation Myocardial Dysfunction and Improves Survival in a Rat Model of Cardiac Arrest and Resuscitation

Effects of the Selective NLRP3-Inflammasome Inhibitor MCC950 on Post-Resuscitationyocardial and Cerebral Function in a Rat Model of Cardiopulmonary Resuscitation

Mitochondrial derived peptide MOTS‐c prevents the development of heart failure under pressure overload conditions in mice

Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling

Low-intensity pulsed ultrasound treatment mitigates ventricular arrhythmias via inhibiting microglia-mediated neuroinflammation in heart failure rat model

Knockout of MD1 Contributes to Sympathetic Hyperactivity and Exacerbates Ventricular Arrhythmias Following Heart Failure with Preserved Ejection Fraction Via NLRP3 Inflammasome Activation

Targeted Ablation Of Cardiac Sympathetic Neurons Improves Ventricular Electrical Remodelling In A Canine Model Of Chronic Myocardial Infarction

Abrogation of CC Chemokine Receptor 9 Ameliorates Ventricular Electrical Remodeling in Mice After Myocardial Infarction